Clinical Trials Logo
  1. Home
  2. Hepatopulmonary Syndrome
  3. NCT03435406

Investigation of the Prevalence of Hepatopulmonary Syndrome in Cirrhosis Patients Caused by Hepatitis B in Western China

Hepatopulmonary Syndrome Clinical Trial

Official title:
Investigation of the Prevalence of Hepatopulmonary Syndrome in Cirrhosis Patients Caused by Hepatitis B in Western China

Clinical Trial Summary

to investigate the prevalence of hepatopulmonary syndrome in cirrhosis patients caused by Hepatitis B in western China

Clinical Trial Description

Hepatopulmonary syndrome (HPS) occurs in approximately 4%-29% of cirrhotic patients and influences mortality. China has 100 million Hepatitis B virus (HBV) carriers and Chronic HBV infection is well-recognized risk factor for cirrhosis.But little is known about the prevalence of HPS in cirrhosis patients caused by HBV in western China. The aim of this study was to investigate the HPS incidence, and the signs, symptoms, arterial blood gas, and BMP9 in the serum of the patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03435406
Study type Observational
Source Southwest Hospital, China
Contact Yi Bin, PhD
Phone 0086-02368754197
Email tang123a123123@163.com
Status Recruiting
Phase N/A
Start date July 27, 2017
Completion date April 1, 2018
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT01676597 - Efficacy of Pentoxifylline and Rifaximin Combination in Pentoxifylline Refractory Clinical and Subclinical Hepatopulmonary Syndrome N/A
Terminated NCT01518595 - Bosentan for Treatment of Hepatopulmonary Syndrome in Patients With Liver Cirrhosis Phase 2
Completed NCT00362752 - A Pilot Study of Norfloxacin for Hepatopulmonary Syndrome Phase 2
Active, not recruiting NCT03092401 - Hepatopulmonary Syndrome and Postoperative Complications After Liver Transplantation : A Case-control Study N/A
Not yet recruiting NCT05373134 - Efficacy and Safety of Pentoxifylline in Improving Oxygenation in Hepatopulmonary Syndrome N/A
Terminated NCT02021929 - Sorafenib for Hepatopulmonary Syndrome Phase 2
Completed NCT02148536 - Effect of Transjugular Intrahepatic Portosystemic Shunt on Oxygenation in Cirrhotic Patients With Hepatopulmonary Syndrome
Terminated NCT00593658 - Pilot Study of Pentoxifylline for Hepatopulmonary Syndrome Phase 1
Recruiting NCT04004104 - Supine Exercise in Hepatopulmonary Syndrome Patients With Orthodeoxia N/A
Recruiting NCT04577001 - Letrozole in Patients With Hepatopulmonary Syndrome Phase 2